Aurobindo Pharma share news, announcements and annual reports
NSE: AUROPHARMABSE: 524804Pharmaceuticals & BiotechnologyMid Cap
Aurobindo Pharma Limited · Face value ₹1 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Apr 1995 on BSE, Jul 2000 on NSE
Last close ₹1,681.40up ₹21.50 (1.30%)BSE ₹1,677.80
Share price at the NSE close on 30 Oct 2026. Previous close ₹1,659.90.
30 Oct: open ₹1,652.00, high ₹1,687.00, low ₹1,647.20
52-week range of traded prices to 30 Oct 2026
₹1,091.20Low, 30 Oct 2025₹1,740.00High, 24 Sep 2026
- Next results date: the board meets on 4 Nov 2026 to consider: financial results and dividend. The notice · Results calendar
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹96,744 Cr138th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 26.06
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 2.55
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- Nonein the last 12 months
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 10.5%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 11.5%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 0.20
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 9,52,65057.5% delivered
Aurobindo Pharma share news and announcements
1,689 announcements, routine notices left out, newest first. Page 32 of 34.
Mar 2009
18 Mar · Business
Press release dated March 18, 2009 titled "Aurobindo Pharma receives three new registrations from MCC- South Africa". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.18 Mar · Limited Review Report
Auditors have conducted the limited review for the un-audited financial results for the quarter ended December 31,2008. A copy of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.12 Mar · Business
Press release dated March 12, 2009 titled "Aurobindo Pharma receives tentative approval for Lopinavir/Ritonavir Tablets." A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.4 Mar · Business
Press release dated March 04, 2009 titled "Aurobindo Pharma receives tentative approval for Escitalopram Oxalate Tablets." A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.3 Mar · Business
Press release dated March 03, 2009 titled "Aurobindo Pharma Announces Licensing and Supply Agreement with Pfizer for Supply of Finished Dosage Products." A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.2 Mar · Business
Press release dated March 02, 2009 titled "Aurobindo Pharma receives first product approval from TGA, Australia for Lisinopril (as dihydrate) Tablets." A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.
Feb 2009
20 Feb · Business
Press release dated February 20, 2009 titled "Aurobindo Pharma receives tentative approval for Tenofovir Disoproxil Fumarate Tablets." A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.13 Feb · Disclosure
Disclosure pursuant to Regulation 8A(4) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 1997. The details of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.
Jan 2009
30 Jan · Business
Press release dated January 30, 2009 titled "Q3 FY 2008-09 Results". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.30 Jan · Business
Press release dated January 30, 2009, titled "Q3 FY2008-09 Results". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.30 Jan · Dividend
Board of Directors of the Company at its meeting held on January 30, 2009 has approved payment of an interim dividend @ 60% i.e. Rs. 3/- (Rupees three only) per Equity Share of Rs. 5/- (Rupees five only) each to the members of the Company for the Current Financial Year 2008-2009.30 Jan · Results
Standalone Results for the quarter ended on 31-DEC-2008 as follows: Net Sales of Rs. 67678 lacs for quarter ending on 31-DEC-2008 against Rs. 51078 lacs for the quarter ending on 31-DEC-2007. Net Profit / (Loss) of Rs. 4072 lacs for the quarter ending on 31-DEC-2008 against Rs. 5525 lacs for the quarter ending on 31-DEC-2007.30 Jan · Results
Consolidated Results for the quarter ended on 31-DEC-2008 as follows: Net Sales of Rs. 73511 lacs for quarter ending on 31-DEC-2008 against Rs. 56956 lacs for the quarter ending on 31-DEC-2007. Net Profit / (Loss) of Rs. 4184 lacs for the quarter ending on 31-DEC-2008 against Rs. 4444 lacs for the quarter ending on 31-DEC-2007.20 Jan · Board meeting
To consider among other business, the Un-audited Financial Results of the Company for the quarter ended December 31, 2008. The Board will also consider the proposal of payment of Interim Dividend for the year 2008-2009. Further, February 06, 2009 is being fixed as the Record date for the purpose of ascertaining the eligibility of shareholders for payment of Interim Dividend, if any, to be declared by the Board of Directors at the said meeting.16 Jan · Business
Press release dated January 16, 2009, titled "Aurobindo Pharma receives final approval for Levetiracetam tablets and oral solution". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.6 Jan · Business
Press release dated January 06, 2009, titled "Aurobindo Pharma receives approval for Gabapentin Capsules from Health Canada ." A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.
Dec 2008
31 Dec · Business
Press release dated December 31, 2008, titled "Aurobindo Pharma receives final approval for Stavudine Capsules and Oral Solution." A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.24 Dec · Business
Press release dated December 24, 2008, titled "Aurobindo Pharma receives approval for Terbinafine Tablets from Health Canada". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.22 Dec · Business
Press release dated December 22, 2008, titled "Aurobindo Pharma receives four new registrations from MCC- South Africa". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.22 Dec · Business
Press release dated December 22, 2008, titled "Aurobindo Pharma receives tentative approval for its New Drug Application (NDA) Abacavir Sulfate / Lamivudine Tablets 60/30mg". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.19 Dec · Foreign Currency Convertible Bonds
In accordance with the press release from RBI dated December 6, 2008 and relevant policy, as amended from time to time, the Company contemplates to buy back a portion of their outstanding FCCBs. Such purchase shall be effected subject to the availability of sufficient funds with the company and subject to prevailing market conditions. The company has appointed Barclays Capital for the same.17 Dec · Business
Press release dated December 17, 2008, titled "Aurobindo Pharma receives tentative approval for its New Drug Application (NDA) Efavirenz Tablets 100mg". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.5 Dec · Business
Press release dated December 05, 2008, titled, "Aurobindo Pharma receives tentative approval for Perindopril Erbumine Tablets and Escitalopram Oxalate Oral Solution". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.
Nov 2008
7 Nov · Business
Press release dated November 07, 2008, titled, "Aurobindo Pharma receives final approval for Sertraline Hydrochloride Oral Concentrate". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.
Oct 2008
31 Oct · Business
Press release dated October 31 2008, with respect to unaudited financial results for the quarter ended September 30, 2008. A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.31 Oct · Results
Standalone Results for the half year ended on 30-SEP-2008 as follows: Net Sales of Rs. 127191 lacs for half year ending on 30-SEP-2008 against Rs. 109155 lacs for the half year ending on 30-SEP-2007. Net Profit / (Loss) of Rs. 137 lacs for the half year ending on 30-SEP-2008 against Rs. 15946 lacs for the half year ending on 30-SEP-2007.31 Oct · Results
Consolidated Results for the half year ended on 30-SEP-2008 as follows: Net Sales of Rs. 138065 lacs for half year ending on 30-SEP-2008 against Rs. 116072 lacs for the half year ending on 30-SEP-2007. Net Profit / (Loss) of Rs. (2200) lacs for the half year ending on 30-SEP-2008 against Rs. 12435 lacs for the half year ending on 30-SEP-2007.31 Oct · Results
Consolidated Results for the quarter ended on 30-SEP-2008 as follows: Net Sales of Rs. 70099 lacs for quarter ending on 30-SEP-2008 against Rs. 62838 lacs for the quarter ending on 30-SEP-2007. Net Profit / (Loss) of Rs. (3842) lacs for the quarter ending on 30-SEP-2008 against Rs. 6232 lacs for the quarter ending on 30-SEP-2007.31 Oct · Results
Standalone Results for the quarter ended on 30-SEP-2008 as follows: Net Sales of Rs. 62468 lacs for quarter ending on 30-SEP-2008 against Rs. 61160 lacs for the quarter ending on 30-SEP-2007. Net Profit / (Loss) of Rs. (3850) lacs for the quarter ending on 30-SEP-2008 against Rs. 10092 lacs for the quarter ending on 30-SEP-2007.22 Oct · Board meeting
To consider among other business, the Un-audited Financial Results of the Company for the quarter ended September 30, 2008.14 Oct · Business
Press release dated October 13, 2008, titled "Aurobindo Pharma receives final approval for Risperidone Tablets". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.10 Oct · Business
Press release dated October 10, 2008, titled "Aurobindo Pharma receives final approval for Fluconazole Tablets". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.10 Oct · Business
Press release dated October 10, 2008, titled "Aurobindo Pharma receives final approval for Cyclobenzaprine Hydrochloride Tablets". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.
Sep 2008
25 Sep · Business
Press release dated September 25, 2008, titled "Aurobindo Pharma receive final approval for Didanosine Delayed Release Capsules". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.23 Sep · Business
Press release dated , September 23, 2008, titled "Aurobindo Pharma awarded the INDIASTAR 2008 for Packaging Excellence". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.17 Sep · Business
Press release dated September 17, 2008, titled "Aurobindo Pharma receives tentative approval for its New Drug Application (NDA) Abacavir Sulfate 60mg Tablets". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.8 Sep · Business
Press release dated September 08, 2008, titled " Aurobindo Pharma receives tentative approval for Abacavir Sulfate / Lamivudine Tablets". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.2 Sep · Limited Review Report
Auditor's have conducted the limited review of the unaudited financial results for the quarter ended June 30, 2008. A copy of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.
Aug 2008
25 Aug · Meeting
Outcome of the Annual General Meeting of the company held on August 20, 2008. The details of the business transacted at the AGM shall be available on the NSE website (http://www.nseindia.com) under Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.21 Aug · Business
Press release dated August 21, 2008, titled " Aurobindo Pharma receives tentative approval for Losartan Potassium tablets". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.11 Aug · Business
Press release dated August 11, 2008, titled " Aurobindo Pharma receives final approval for Cefazolin for Injection USP". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.7 Aug · Business
Press release dated August 05, 2008, titled " Aurobindo Pharma receives final approval for Alendronate Sodium Tablets". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.1 Aug · Business
Press release dated August 01, 2008, titled " Aurobindo Pharma's Sterile Injectable Formulation line of Unit VIB, India has received the final approval for Ceftriaxone for Injection USP by USFDA". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.
Jul 2008
30 Jul · Business
Press release dated July 30 2008, with respect to unaudited financial results for the quarter ended June 30, 2008. A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.30 Jul · Results
Standalone Results for the quarter ended on 30-JUN-2008 as follows: Net Sales of Rs. 64723 lacs for quarter ending on 30-JUN-2008 against Rs. 47995 lacs for the quarter ending on 30-JUN-2007. Net Profit / (Loss) of Rs. 3987 lacs for the quarter ending on 30-JUN-2008 against Rs. 5854 lacs for the quarter ending on 30-JUN-2007.30 Jul · Results
Consolidated Results for the quarter ended on 30-JUN-2008 as follows: Net Sales of Rs. 67966 lacs for quarter ending on 30-JUN-2008 against Rs. 53234 lacs for the quarter ending on 30-JUN-2007. Net Profit / (Loss) of Rs. 1642 lacs for the quarter ending on 30-JUN-2008 against Rs. 6173 lacs for the quarter ending on 30-JUN-2007.22 Jul · Meeting
Annual General Meeting of the Company will be held on August 20, 2008. Accordingly, the Register of Members and Share Transfer Books of the Company will be closed from August 13, 2008 to August 20, 2008 (both days inclusive) for the purpose of Annual General Meeting and for payment of dividend for the year 2007-08.16 Jul · Business
Press release dated July 16, 2008, titled "Fitch Assigns 'A+(ind)/F1+(ind)' to Aurobindo Pharma's Bank Loan Facilities". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.15 Jul · Board meeting
To consider among other business, the Un-audited Financial Results of the Company for the quarter ended June 30, 2008.
Jun 2008
18 Jun · Updates
Vide notes to Accounts in the audited financial results for the year ended March 31, 2008 (taken on record by the Board of Directors of the Company at its meeting held on June 18, 2008) that : "Premium on redemption of USD 255.5 Million zero coupon Foreign Currency Convertible Bond is contingent in nature, the outcome of which is dependent on uncertain future events. During the quarter, the Company has formed new step-down subsidiaries viz, Agile pharma(Malta) Ltd, Aurbindo Pharma(Italia) S.r.l Laboratories Aurobindo Sociedad Limitada, Spain and Aurobindo Pharma (Ireland) Limited."